2016
DOI: 10.1177/1932296816682032
|View full text |Cite
|
Sign up to set email alerts
|

Accuracy Assessment of a Blood Glucose Monitoring System for Self-Testing with Three Test Strip Lots Following ISO 15197:2013/EN ISO 15197:2015

Abstract: The International Organization for Standardization (ISO) standard 15197:2013 and the European harmonized version EN ISO 15197:2015 are used to establish guidelines around acceptable performance for blood glucose monitoring systems (BGMSs). The minimum accuracy performance criteria are 95% of the system's results shall fall within either ±15

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
2
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 1 publication
0
2
0
Order By: Relevance
“…The importance of this standard and the European version EN ISO 15197:2015 is the establishment of rules about the acceptable performance of blood glucose monitoring devices. The standard states that readings from the device shall fall within ±15 mg/dL of the average values measured with the comparison method for blood glucose concentrations <100 mg/dL and within ±15 % for blood glucose concentrations ≥100 mg/dL for at least 95% of the system's results (Breitenbeck et al, 2017).…”
Section: Validationmentioning
confidence: 99%
“…The importance of this standard and the European version EN ISO 15197:2015 is the establishment of rules about the acceptable performance of blood glucose monitoring devices. The standard states that readings from the device shall fall within ±15 mg/dL of the average values measured with the comparison method for blood glucose concentrations <100 mg/dL and within ±15 % for blood glucose concentrations ≥100 mg/dL for at least 95% of the system's results (Breitenbeck et al, 2017).…”
Section: Validationmentioning
confidence: 99%
“…Different systems for SMBG are constantly evaluated for interactions with potentially interfering substances. 2,3 Such clinically relevant interferences show up with a number of widely used drugs, to a degree that has implications for diabetes management of patients with DM. 2,[4][5][6] To ensure safety and efficacy of SMBG, interferences should be tested especially for newer classes of clinically used drugs patients with DM might be exposed to.…”
mentioning
confidence: 99%